Core Insights - Journey Medical Corporation reported revenue of $16.08 million for the quarter ended December 2025, marking an 18.1% year-over-year increase, but fell short of the Zacks Consensus Estimate by 15.68% [1] - The company reported an EPS of -$0.04, which is an improvement compared to $0.08 a year ago, resulting in a positive EPS surprise of 27.27% against the consensus estimate of -$0.06 [1] Revenue Breakdown - Total net product revenue from Accutane was $3.06 million, exceeding the average estimate of $2.77 million, but reflecting a year-over-year decline of 20.9% [4] - Total net product revenue from EmrosiTM was $5 million, significantly lower than the estimated $7.42 million [4] - Total net product revenue from Qbrexza was $5.54 million, also below the estimated $6.97 million, with a year-over-year change of -2.4% [4] Stock Performance - Journey Medical's shares have decreased by 21.7% over the past month, contrasting with a 5% decline in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 3 (Hold), suggesting it may perform in line with the broader market in the near term [3]

Core Insights - Journey Medical achieved a significant milestone in 2025 with the commercial launch of EMROSI, an oral treatment for rosacea, and reported improved profitability metrics as the product gains traction [5][6] Product Performance - EMROSI generated approximately $14.7 million in net sales during the three quarters it was available in 2025, with around 53,000 total prescriptions written [4][8] - The refill behavior for EMROSI improved, with a ratio of 1.4 refills per new prescription by the end of 2025, indicating strong ongoing demand [1][8] - The company ended 2025 with over 3,500 unique dermatology prescribers for EMROSI, surpassing its initial goal [2] Financial Results - Full-year 2025 revenue rose to $61.9 million, a 10% increase from $56.1 million in 2024, driven by the launch of EMROSI [6][17] - The gross margin for 2025 was reported at 66.2%, up from 62.8% in 2024, attributed to a favorable product mix and lower inventory costs [21] - The GAAP net loss narrowed to $11.4 million in 2025, compared to a loss of $14.7 million in 2024, reflecting improved financial performance [21] Market Access and Coverage - Journey Medical reported access to approximately 100 million commercial covered lives, with contracts with two of the top three U.S. group purchasing organizations (GPOs) [7][11] - The company expects to contract with the third major GPO by early second quarter of 2026, which is anticipated to enhance market access [11] Future Outlook - The company anticipates remaining adjusted EBITDA positive in 2026, supported by expected sales growth and the leverage of its commercial organization [20] - Journey plans to launch one to two additional dermatology products later in 2026, indicating a focus on portfolio expansion [21][22] - Management expects gradual improvement in gross-to-net dynamics as formulary milestones are reached throughout 2026 [12][20]

Financial Data and Key Metrics Changes - Total revenues for 2025 were $61.9 million, a 10% increase from $56.1 million in 2024, driven by the successful launch of EMROSI [17] - Gross margins improved to 66.2% in 2025 from 62.8% in 2024, reflecting a favorable product mix and lower inventory costs [17] - The company reported a GAAP net loss of $11.4 million, or $0.47 per share, compared to a loss of $14.7 million, or $0.72 per share in 2024 [18] - Adjusted EBITDA was positive at $2.9 million for 2025, up from $800,000 in 2024, indicating progress towards sustainable profitability [18] Business Line Data and Key Metrics Changes - EMROSI achieved $14.7 million in net sales during the three quarters it was available in 2025, with approximately 53,000 prescriptions written [5][7] - The total prescription volume for EMROSI grew nearly 50% sequentially in Q4 compared to Q3 [8] - The company ended 2025 with approximately 3,500 unique prescribers for EMROSI, surpassing its initial goal of 3,200 [9] Market Data and Key Metrics Changes - Approximately 100 million commercial covered lives have access to EMROSI, with contracts in place with two of the top three group purchasing organizations in the U.S. [10] - The company anticipates contracting with the third major GPO by late Q1 or early Q2 of 2026 [10] Company Strategy and Development Direction - The company aims to improve profitability and expand the commercial footprint of EMROSI while launching one or two additional dermatology products in 2026 [19][25] - Focus on building positive physician and patient experiences with EMROSI to drive prescription demand and improve reimbursement rates [11][12] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in continued sales growth and profitability, expecting to remain adjusted EBITDA positive in 2026 [7] - The company anticipates improved reimbursement rates and reduced reliance on co-pay bridging programs as coverage expands [11] - Management highlighted the importance of clinical data and publications in supporting EMROSI's market adoption and reimbursement evaluations [12][14] Other Important Information - The company ended 2025 with a cash position of approximately $24 million, up from $20.3 million at the end of 2024 [18] - Working capital at year-end was $29.4 million, an increase of $16.4 million from the previous year [19] Q&A Session Summary Question: Insights on EMROSI prescriptions trends for Q1 - Management noted that Q1 typically sees a slowdown due to insurance deductible resets and severe weather but expects Q1 prescriptions to surpass Q4 numbers [28][29] Question: Expectations for sequential growth in Q2 - Management indicated that momentum is building and expects Q2 to be stronger than Q1, with a run rate of over 126,000 prescriptions annually [30][46] Question: Clarification on revenue per script and gross-to-net expectations - Management explained that Q4's lower revenue per script was due to reimbursement mix and expects improvements in gross-to-net as reimbursement progresses [32][35][58] Question: Commentary on accounts receivable increase in Q4 - Management confirmed that most of the accounts receivable has been collected and attributed the increase to timing [66] Question: Future gross margins outlook as EMROSI gains coverage - Management expressed optimism for improved margins as EMROSI and other high-margin products become a larger part of the revenue mix [67]

Financial Data and Key Metrics Changes - Total revenues for 2025 were $61.9 million, a 10% increase from $56.1 million in 2024, driven by the successful launch of EMROSI [17] - Gross margins improved to 66.2% in 2025 from 62.8% in 2024, reflecting a favorable product mix and lower inventory costs [17] - GAAP net loss narrowed to $11.4 million ($0.47 per share) in 2025 from a loss of $14.7 million ($0.72 per share) in 2024 [18] - Adjusted EBITDA was positive at $2.9 million for 2025, compared to $800,000 in 2024, indicating progress towards sustainable profitability [18] Business Line Data and Key Metrics Changes - EMROSI achieved $14.7 million in net sales during its first three quarters on the market, with approximately 53,000 prescriptions written [5][7] - The total prescription volume for EMROSI grew nearly 50% sequentially in Q4 compared to Q3 [8] - The company ended 2025 with approximately 3,500 unique prescribers for EMROSI, surpassing its initial goal of 3,200 [9] Market Data and Key Metrics Changes - Approximately 100 million commercial covered lives have access to EMROSI, with contracts in place with two of the top three group purchasing organizations in the U.S. [10] - The company anticipates contracting with the third major GPO by late Q1 or early Q2 of 2026 [10] Company Strategy and Development Direction - The company plans to launch one or two additional dermatology products in 2026 to augment its revenue growth [15][25] - Focus on improving profitability through disciplined expense management and margin expansion as EMROSI's commercial footprint grows [19] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in continued sales growth and expects to remain adjusted EBITDA positive in 2026 [7] - The company anticipates improved reimbursement rates and reduced reliance on co-pay bridging programs as coverage expands [11] - Management highlighted the importance of EMROSI's clinical efficacy and safety profile in driving demand and patient refill behavior [12] Other Important Information - The company ended 2025 with a cash position of approximately $24 million, up from $20.3 million at the end of 2024 [18] - Working capital at year-end was $29.4 million, an increase of $16.4 million from the previous year [19] Q&A Session Summary Question: Trends in EMROSI prescriptions for Q1 - Management noted that Q1 typically sees a slowdown due to insurance deductible resets and severe weather but expects Q1 prescriptions to surpass Q4 numbers [28][29] Question: Expectations for Q2 prescriptions - Management anticipates strong momentum in Q2, with expectations for prescription growth to continue [30] Question: Gross-to-net revenue predictions - Management indicated that gross-to-net figures are expected to improve as reimbursement progresses and the mix of reimbursed prescriptions changes [34][35] Question: Inventory movement and accounts receivable - Management confirmed that the increase in accounts receivable was due to timing and that most cash has been collected [66] Question: Future product launches - Management described upcoming product launches as incremental additions to the portfolio, aimed at supporting the base business [70]

Financial Data and Key Metrics Changes - Total revenues for 2025 were $61.9 million, a 10% increase from $56.1 million in 2024, driven by the successful launch of EMROSI [17] - Gross margins improved to 66.2% in 2025 from 62.8% in 2024, reflecting a favorable product mix and lower inventory costs [17] - GAAP net loss narrowed to $11.4 million (47 cents per share) in 2025 from a loss of $14.7 million (72 cents per share) in 2024 [18] - Adjusted EBITDA was positive at $2.9 million for 2025, compared to $800,000 in 2024, indicating progress towards sustainable profitability [18] Business Line Data and Key Metrics Changes - EMROSI achieved $14.7 million in net sales during the three quarters it was available in 2025, with approximately 53,000 total prescriptions written [5][21] - The company reported a total net product revenue growth of 11% for the year, despite pressures on legacy products due to generic competition [5] Market Data and Key Metrics Changes - Approximately 100 million commercial covered lives have access to EMROSI, with contracts in place with two of the top three group purchasing organizations in the U.S. [10] - The company ended 2025 with about 3,500 unique dermatology prescribers for EMROSI, exceeding its initial goal [9] Company Strategy and Development Direction - The company plans to launch one or two additional dermatology products in 2026 to augment its revenue growth [15][23] - Focus on improving profitability and expanding the commercial footprint of EMROSI, with expectations for continued sales growth and margin expansion [19][24] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the continued growth of EMROSI prescriptions, anticipating that Q1 2026 will surpass Q4 2025 numbers [28] - The company expects to see improved reimbursement rates and reduced reliance on co-pay bridging programs as coverage expands in 2026 [11][12] Other Important Information - The company ended 2025 with a solid cash position of approximately $24 million, supporting ongoing operations and growth [6][19] - Management highlighted the importance of clinical data and publications in supporting EMROSI's market adoption and reimbursement discussions [12][13] Q&A Session Summary Question: Trends in EMROSI prescriptions for Q1 - Management noted that Q1 typically sees slower patient visits due to insurance deductible resets but expects strong growth in March and overall Q1 prescriptions to surpass Q4 [27][28] Question: Expectations for sequential growth in Q2 - Management confirmed expectations for strong sequential growth in Q2, driven by the established efficacy of EMROSI and an increase in sales force [29][30] Question: Clarification on gross-to-net revenue per script - Management explained that the lower revenue per script in Q4 was due to a higher proportion of non-reimbursed prescriptions and anticipated improvements in gross-to-net as reimbursement progresses [31][34] Question: Inventory movement and accounts receivable - Management indicated that the increase in accounts receivable was due to timing and that most cash has been collected, impacting Q1 positively [67] Question: Future gross margins and product launches - Management expects gross margins to improve as EMROSI and other high-margin products become a larger part of the sales mix, with incremental product launches planned for the second half of 2026 [68][70]

Core Insights - Journey Medical Corporation reported revenue of $17.63 million for the quarter ended September 2025, reflecting a year-over-year increase of 20.5% [1] - The earnings per share (EPS) was -$0.09, an improvement from -$0.12 in the same quarter last year [1] - The revenue fell short of the Zacks Consensus Estimate of $17.7 million by 0.39%, while the EPS was below the consensus estimate of -$0.08 by 12.5% [1] Financial Performance Metrics - Total net product revenue for Accutane was $2.77 million, which is 30.7% lower than the year-ago figure and below the average estimate of $3.54 million [4] - Total net product revenue for EmrosiTM was reported at $4.88 million, compared to the estimated $6.35 million, indicating a significant shortfall [4] - Total net product revenue for Qbrexza was $7.36 million, slightly exceeding the estimated $6.67 million, but still showing a year-over-year decline of 2.9% [4] Stock Performance - Journey Medical's shares have increased by 25.7% over the past month, outperforming the Zacks S&P 500 composite, which rose by 4.6% [3] - The stock currently holds a Zacks Rank 3 (Hold), suggesting it may perform in line with the broader market in the near term [3]

Financial Data and Key Metrics Changes - Journey Medical reported total revenues of $17.6 million for Q3 2025, a 21% increase from $14.9 million in Q3 2024, driven by the successful launch of Amrosi [5][13] - Gross margin decreased to 67.4% in Q3 2025 from 69.4% in Q3 2024, but showed steady improvement from 63.5% in Q1 2025 and 67.1% in Q2 2025 [13][14] - The company reported a GAAP net loss of $2.3 million, or $0.09 per share, compared to a loss of $2.4 million, or $0.12 per share, in the same period last year [15] - EBITDA improved from a loss of $1 million in Q3 2024 to a loss of $500,000 in Q3 2025, with adjusted EBITDA reaching $1.7 million compared to $300,000 in the prior year [15][16] Business Line Data and Key Metrics Changes - Emrosi contributed $4.9 million to revenue in Q3 2025, a 75% increase from Q2 2025, while legacy products like Qbrexza, Accutane, and Zilxi saw a 16% year-over-year decline due to generic competition [5][6] - Total prescriptions for Emrosi grew by approximately 146% from Q2 to Q3 2025, with 18,198 prescriptions in Q3 compared to 7,394 in Q2 [6][17] - The number of unique prescribers for Amrosi increased by approximately 50% to over 2,700, indicating strong initial adoption [9][11] Market Data and Key Metrics Changes - Over $100 million of the $187 million commercial lives currently have access to Amrosi, with successful contracting with two of the three largest GPOs [7][8] - Physician feedback on Amrosi has been positive, with prescribers noting early efficacy and strong refill rates, indicating a favorable reception in the market [8][10] Company Strategy and Development Direction - The company aims to establish Amrosi as the standard of care for rosacea treatment, with expectations of peak annual net sales exceeding $200 million in the U.S. and $300 million globally [17][18] - Journey Medical is focused on disciplined expense management and margin expansion while scaling Amrosi's commercial footprint [16][18] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving sustainable EBITDA positivity in Q4 2025, highlighting the transformational potential of 2025 for the company [18] - The company anticipates that as drug coverage increases, reliance on the copay assistance program will decrease, with significant gains expected in 2026 [21][22] Other Important Information - The company is actively participating in dermatology medical conferences to build awareness and momentum for Amrosi [9][11] - The launch of Amrosi is expected to create a snowball effect in prescription growth as more physicians gain confidence in the product [25][26] Q&A Session Summary Question: Usage of patient assistance program for Amrosi - Management noted that the copay assistance program will see reduced reliance as reimbursement improves, with significant gains expected in 2026 [21][22] Question: Focus on breadth vs. depth of prescribers - The company is focusing on both breadth and depth, with efforts to convert new prescribers into consistent writers while expanding the prescriber base [24][25] Question: Revenue per script fluctuations - Management acknowledged variability in gross to net revenue and indicated that improvements are expected as more GPOs are contracted [29][30] Question: Launch curve expectations - Management expressed optimism about a consistently growing and potentially accelerating launch curve based on current performance [32] Question: Accutane's performance amidst generic competition - Management indicated that Accutane appears stable, with a recent uptick in performance, although competition remains a concern [33] Question: Retention rate of prescribers - Management did not provide specific retention rates but noted ongoing trial and adoption among new prescribers [37][40] Question: Qbrexza's performance and overlap with Amrosi - Management reported good growth for Qbrexza despite competition, with effective overlap in marketing strategies for both products [41][42]

Financial Data and Key Metrics Changes - Total revenues for Q3 2025 were $17.6 million, a 21% increase from $14.9 million in Q3 2024, driven by the successful launch of Emrosi [13][18] - Gross margin decreased to 67.4% in Q3 2025 from 69.4% in Q3 2024, but showed steady improvement from 63.5% in Q1 to 67.1% in Q2 [14][15] - GAAP net loss was $2.3 million, or $0.09 per share, compared to a loss of $2.4 million, or $0.12 per share, in the same period last year [15] - EBITDA improved from a loss of $1 million in Q3 2024 to a loss of $500,000 in Q3 2025, while adjusted EBITDA was positive at $1.7 million [16] Business Line Data and Key Metrics Changes - Emrosi contributed $4.9 million in Q3 2025, a 75% increase compared to Q2 2025, with total prescriptions growing approximately 146% [5][6] - Legacy products, including Qbrexa, Accutane, and Amzeeq, saw a 16% year-over-year decline in revenue due to generic competition impacting Accutane [5] - Amzeeq's total prescription growth indicates strong commercial execution, with a one-to-one ratio of refills to new prescriptions [8][9] Market Data and Key Metrics Changes - Over $100 million of the $187 million commercial lives currently have access to Amzeeq, with successful contracting with two of the three largest GPOs [7] - The number of unique prescribers for Emrosi increased by approximately 50% to over 2,700, demonstrating substantial progress in product adoption [9] Company Strategy and Development Direction - The company aims to position Emrosi as the standard of care for rosacea treatment, targeting peak annual net sales of over $200 million in the U.S. and over $300 million globally [18] - Focus on disciplined expense management and margin expansion to improve profitability and sustain revenue growth [16][18] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving sustainable EBITDA positivity in Q4 2025, indicating a transformational year for the company [18] - Positive physician feedback on Emrosi suggests strong initial adoption and potential for continued growth [8][50] Other Important Information - The company is actively participating in key dermatology medical conferences to build awareness and momentum for Emrosi [9][10] - The copay assistance program is currently bridging the gap until broader health plan formulary adoption occurs [7] Q&A Session Summary Question: Usage of patient assistance program for Amzeeq - Management noted that the copay assistance program will see reduced reliance as reimbursement improves, with significant gains expected in 2026 [22][23] Question: Focus on breadth vs. depth of prescribers - The strategy involves both expanding the number of prescribers and increasing the volume of prescriptions from existing prescribers, with expectations for a snowball effect as confidence builds [25][26] Question: Revenue per script fluctuations - Management acknowledged variability in gross to net revenue due to early-stage dynamics and expected improvements with the addition of the third GPO in early 2026 [33][34] Question: Launch curve perspective - All indicators suggest a positive and potentially accelerating launch curve, with expectations for increased new prescriptions and refills [40][41] Question: Accutane's performance amidst generic competition - Management indicated that Accutane appears stable, with a recent uptick in performance, although competition remains a factor [42] Question: Retention rate of prescribers - No specific retention data was provided, but management noted ongoing trial and adoption among new prescribers [46][50] Question: Qbrexa's growth management - Qbrexa is expected to maintain single-digit growth year-over-year, with effective management of the overlap with Amzeeq [51]

Group 1: Fund Performance - Summers Value Fund LP reported a net return of -1.8% in Q2 2025, underperforming the Russell 2000 Index ETF (IWM) which returned 8.5% and the Russell 2000 Value Index ETF (IWN) which returned 4.9% [1] - Year-to-date, the fund is down 12.8% net, compared to -1.8% and -3.2% returns for the respective indexes [1] Group 2: Journey Medical Corporation Overview - Journey Medical Corporation (NASDAQ:DERM) focuses on developing and commercializing pharmaceutical products for dermatological conditions [2] - The stock of Journey Medical Corporation had a one-month return of -1.35% but gained 41.47% over the last 52 weeks, closing at $7.30 per share with a market capitalization of $192.062 million on September 19, 2025 [2] Group 3: Investment Insights on Journey Medical Corporation - The fund began building a position in Journey Medical Corporation in February, highlighting its products such as Accutane for acne treatment and Qbrexza for hyperhidrosis [3] - Journey Medical Corporation generated $55 million in revenue in 2024, with a modest operating loss [3] - The company is led by CEO Claude Marauoi and a team with significant experience from Medicis, a dermatology company previously acquired for $2.6 billion [3]

Summary of Journey Medical Corp (DERM) Conference Call - August 20, 2025 Company Overview - **Company Name**: Journey Medical Corporation - **Ticker Symbol**: DERM - **Industry**: Pharmaceutical, specifically focused on dermatology - **Founded**: Approximately 10 years ago, went public in November 2021 - **Average Daily Volume**: About 150,000 shares - **Outstanding Shares**: Approximately 23 million shares [6][5] Key Products and Market Focus - **Market Size**: The dermatology market is valued at nearly $6 billion [7] - **Primary Disease States**: Rosacea, hyperhidrosis, and acne [7] - **Key Product**: Imrozi, launched in April 2025, is the first product developed by Journey Medical and approved by the FDA in November 2024 [8][7] - **Core Business Revenue**: Approximately $55 million in net revenue for 2024 without Imrozi [8] Product Details - **Imrozi**: - Indicated for the treatment of inflammatory lesions, papules, and pustules of rosacea in adults - Lowest strength of minocycline available at 40 mg, with a once-daily dosage [15][16] - Demonstrated superior efficacy compared to Oratia, the only other oral treatment for rosacea [17][19] - Safety profile similar to placebo, with minimal adverse events [27][28] Clinical Trial Results - **Efficacy**: - Over 60% greater IgA success compared to Oratia and over 120% compared to placebo [20] - Approximately 30% greater inflammatory lesion reduction compared to Oratia and over 65% compared to placebo [21] - Fast-acting results observed as early as two weeks [24] Market Access and Growth Strategy - **Market Access**: - Approximately 100 million lives have access to Imrozi, with expectations for growth as payer acceptance increases [35][54] - **Prescription Growth**: - Rapid increase in prescriptions from 1,200 in April to over 5,200 in July 2025 [32] - Unique prescribers increased from 600 to over 1,800 [34][48] - **Sales Territories**: 35 sales territories covering 80 of the top 50 MSAs in the U.S., accessing about 70% of dermatology prescriptions [11][12] Financial Outlook - **Current Run Rate**: Approximately $60 million annually, nearing breakeven [49] - **EBITDA Positive**: Expected to achieve EBITDA positivity later in 2025 due to contributions from Imrozi [38][48] - **Out-Licensing Strategy**: Successful past deals, including a $20 million non-dilutive capital deal for QBREXZA [41][52] Long-Term Strategy - **Focus Areas**: - Continued growth of Imrozi, QBREXZA, and Accutane - Out-licensing opportunities to generate additional capital - Building a strong presence in dermatology with a robust product portfolio [57][40] Conclusion - Journey Medical is positioned for significant growth in the dermatology market with the launch of Imrozi and a strong sales strategy. The company aims to leverage its existing products and expand its market presence while focusing on achieving profitability and sustainable growth in the coming years [42][57].